Syntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedAC
Allegis Capital
Activity from announced rounds
Activity in this selectionaurora-venture-investments-19a368ca
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $66.4M 2 disclosed · full round size, not this investor’s share